Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-86.76m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clearside Biomedical Inc | 7.52m | -33.46m | 97.92m | 30.00 | -- | -- | -- | 13.01 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Boundless Bio Inc | 0.00 | -57.72m | 97.92m | 72.00 | -- | 0.5463 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Sagimet Biosciences Inc | 2.00m | -29.25m | 101.09m | 10.00 | -- | 0.5467 | -- | 50.55 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Citius Pharmaceuticals Inc | 0.00 | -39.77m | 103.00m | 22.00 | -- | 1.20 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 105.09m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 105.15m | 9.00 | -- | 18.99 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
Relmada Therapeutics Inc | 0.00 | -86.76m | 105.91m | 20.00 | -- | 1.72 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Leap Therapeutics Inc | 0.00 | -60.34m | 105.99m | 54.00 | -- | 1.61 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Checkpoint Therapeutics Inc | 78.00k | -42.47m | 108.49m | 23.00 | -- | -- | -- | 1,390.94 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
ALX Oncology Holdings Inc | 0.00 | -171.44m | 109.03m | 74.00 | -- | 0.6815 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Annovis Bio Inc | 0.00 | -43.02m | 110.57m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Anixa Biosciences Inc | 0.00 | -12.36m | 111.98m | 4.00 | -- | 5.14 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Citius Oncology Inc | 0.00 | 1.93m | 114.09m | -- | 6.61 | 0.2309 | 59.00 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
INmune Bio Inc | 85.00k | -37.74m | 115.74m | 11.00 | -- | 2.77 | -- | 1,361.65 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Verastem Inc | 10.00m | -89.49m | 115.90m | 73.00 | -- | 4.11 | -- | 11.59 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.25m | 4.13% |
Deep Track Capital LPas of 31 Mar 2024 | 1.24m | 4.11% |
Vestal Point Capital LPas of 31 Mar 2024 | 1.20m | 3.98% |
Acadian Asset Management LLCas of 30 Jun 2024 | 1.19m | 3.96% |
Parsons Capital Management, Inc.as of 30 Jun 2024 | 975.95k | 3.23% |
Opaleye Management, Inc.as of 31 Mar 2024 | 759.00k | 2.52% |
Palo Alto Investors LPas of 31 Mar 2024 | 732.40k | 2.43% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 630.25k | 2.09% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 567.32k | 1.88% |
Millennium Management LLCas of 31 Mar 2024 | 341.45k | 1.13% |